Home > Formulary : Adult > Recent Decisions > 2021 >
Decisions 16th March 2021
Decisions 16th March 2021
At the meeting on the 16th March the following decisions were agreed
New Drug Requests
Approved
OralVac®(TLS Red)
- for grass, tree pollen and house dust mite allergy, for use by immunology only, commissioned by NHS England
Potassium Chloride 600mg (8mmol) modified release tablets (TLS Red)
- for short courses for patients where other preparations are not suitable or tolerated
Potassium Chloride 600mg (8mmol) modified release tablets (TLS Amber, no SCP)
- for long term treatment courses for patients where other preparations are not suitable or tolerated
Qlaira ® (estradiol valerate, dienogest) (TLS Amber, no SCP)
- as an option for patients with premature ovarian insufficiency requiring contraception and HRT cover where standard oral contraceptives are not suitable and patients have completed puberty.
- JFG did not approve this as a standard contraception for other patients outside of this cohort
Shared Care Protocols/TLS changes
New SCPs:
- Desmopressin oral lyophilisates (Noqdirna) for nocturia for adult patients, TLS Amber 3 months
- Opicapone for Parkinson's Disease, TLS Amber 3 months
- Rivaroxaban 2.5mg tablets, in combination with aspirin 75mg, for prevention of atherothrombotic events in line with NICE TA 607
Updated SCPs:
- Lithium on new AWP template, TLS Amber 3 months
- Azathioprine for autoimmune hepatitis, TLS Amber 3 months
- Mercaptopurine for autoimmune hepatitis, TLS Amber 3 months
Other Formulary Decisions:
- Further work was needed regarding the applications for testosterone gel for low libido for postmenopausal women
- Aminophylline (Phyllocontin brand) removed as discontinued. Parental aminophylline changed from TLS Green to TLS Red
- Sucralfate changed from TLS Green to TLS Blue, licensed formulation now available
- Ulipristal (Esmya) changed from TLS Amber to TLS Red and SCP removed due to MHRA alert and formulary review required